Testing a new approach for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced kidney cancer that has spread to other parts of your body (stage IV).
- Your cancer is considered intermediate or high risk according to a standard classification system.
- You are 18 years or older.
- You are able to take care of most daily activities (Karnofsky score of 70% or higher).
- Your blood tests show that your organs (like kidneys and liver) are working well enough.
- You have not had prior treatment for advanced kidney cancer, except possibly some immunotherapy after surgery more than 6 months ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This trial tests a new oral drug (HC-7366) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced clear cell kidney cancer. The goal is to see if adding this new drug can help shrink tumors or slow the cancer's growth.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
Hear when a new Metastatic Kidney Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.